Willow and Suanfarma announce collaboration for the development of high-volume anti-infective API through precision fermentation
SUNNYVALE, California, Oct. 3, 2023 /PRNewswire/ — Willow Biosciences Inc., (“Willow”) (TSX: WLLW) (OTCQB: CANSF) and SUANFARMA today jointly announced the execution of a collaboration agreement for a cell line productivity optimization development for the manufacturing of a high volume anti-infective active pharmaceutical ingredient (“API”) using precision fermentation. Through the partnership, SUANFARMA will have access to Willow’s patented strain optimization technologies to develop a more cost-effective production process.
SUANFARMA has engaged Willow to apply its stress engineering technology platform to enable more cost-effective commercial production of the API at SUANFARMA’s manufacturing site.
“We are pleased to further expand our successful relationship with SUANFARMA, to bring sustainably sourced products to market by leveraging our joint capabilities and their proven, efficient manufacturing resources,” said Chris Savile, President and CEO of Willow. “Together, we see a number of opportunities to create alternative means to more sustainably produce key products for improved human health and well-being and look forward to working with the SUANFARMA team.”
“SUANFARMA CDMO is pleased to further expand our partnership with Willow into commercial product development to expand our portfolio by maximizing product quality at a reduced cost through fermentation technology,” said Daniel Rivero, Industrial Director of SUANFARMA. “Following successful development, we look forward to bringing these life-enhancing products to the market on an industrial scale through our manufacturing site in Europe. SUANFARMA CDMO provides contract development and manufacturing organization services to the market, with a strong track record and experience in fermentation, purification and chemical synthesis technologies under the highest quality standards for the pharmaceutical and biotechnology industry.
SUAFARMA CDMO offers a comprehensive approach to technology transfer, with the goal of reducing risks and improving success within your overall project management strategy. Our platform, known as TT
In March 2023, Willow and SUANFARMA announced an alliance with the intention of working together on existing pharmaceutical and biotechnology capabilities for synthetic molecules, including anti-infectives and other APIs and intermediates for pharmaceutical and natural ingredients designed for the health and wellness and food industries. and drinks. Today’s announcement marks further progress in expanding the relationship by offering an end-to-end synthetic biology solution and expanding the parties’ joint product portfolio.
About WILLOW BIOSCIENCES
Willow develops and produces precision fermented functional ingredients for the health & wellness, food & beverage, and personal care markets. Willow’s FutureGrown™ and BioOxi™ platforms enable large-scale production with sustainability at the core.
About SUANFARMA
SUANFARMA founded in 1993, is a B2B life sciences partner specialized in the development, production and marketing of ingredients for the pharmaceutical, veterinary and nutraceutical industries.
Our CDMO division provides end-to-end integrated solutions for drug substance and intermediate development and commercialization services for complex small molecules. We specialize in helping pharmaceutical, biotechnology and healthcare companies provide fully integrated services that compress time to market and maximize success.
Logo – https://mma.prnewswire.com/media/2234752…
View original content: https://www.prnewswire.com/news-releases/willow-y-suanfarma-anuncian-una-colaboracion-para-el-desarrollo-de-api-antiinfectivo-de-gran-volumen-301943066.html
